For patient 10, the CNA profile observed in the tumour (including focal loss of CDKN2A and CREBBP) was observed in all peripheral sample types taken prior to starting chemotherapy, albeit at lower levels in plasma. This evidence concerns the gene CDKN2A and neoplasm.